Dr. Amesh Adalja, a senior scholar at the Johns Hopkins Bloomberg School of Public Health, discusses the current number of COVID-19 cases in the U.S.

Death rates from the novel coronavirus are lower in hot spots around the world, even as new infections accelerate in what may be the pandemic’s next wave.

People on remdesivir recovered in 10 days, on average, compared with 15 days for those only receiving supportive care like oxygen and IV fluids, according to the results published Oct. 8 in the New England Journal of Medicine.

Johns Hopkins Assistant Professor of Emergency Medicine Lauren Sauer on what has been learned from the coronavirus outbreak at the White House and the example being set by President Donald Trump.

Experts hope this year’s flu shot can help prevent an influenza epidemic paired with another wave of coronavirus, which could overwhelm hospitals and lead to general confusion.

No one really knows what the next few months will bring. But as COVID-19 cases rise in 39 of 50 states, there are a few clues about what's likely to happen, both good and bad.

Dr. Stefan Baral, an associate professor in the department of epidemiology at the Johns Hopkins Bloomberg School of Public Health, coauthors a piece on the disproportionate impact of COVID-19 among the "haves" and "have-nots."

It's looking increasingly likely that a Rose Garden event late last month was ground zero for a spate of coronavirus infections spreading among those with close ties to the White House, including President Trump himself.

The Food and Drug Administration released strengthened rules for authorizing any Covid-19 vaccine on an emergency basis. 

Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation

Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation

Preserving the Scientific Integrity of Getting to COVID-19 Vaccines: From Clinical Trials to Public Allocation